| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、湖南九典制药股份有限公司（以下简称"公司"）通过回购专户持有的 公司股份5,000,000股，不参与本次权益分派。因此，本次权益分派以总股本扣 除公司回购专户中已回购股份后的总股本491,198,771股为基数，向全体股东每 10股派发现金股利人民币3.129649元（含税）。 2、本次权益分派实施后，按公司总股本折算每股现金分红比例计算如下： 公司总股本折算每股现金红利=本次实际现金分红总额÷股权登记日的总股本= （股权登记日的总股本-回购专户中的股份）×每股分红金额÷股权登记日的总 股本=491,198,771×3.129649÷10÷496,198,771=0.3098112元/股，每10股现金 红利为3.098112元。 3、2024年度权益分派 ...

特别提示： 湖南九典制药股份有限公司（以下简称"公司"）于2025年5月15日召开2024 年度股东会，审议通过了《关于2024年度利润分配预案的议案》。近日，公司将 根据相关决议实施2024年度权益分派。 特此公告。 湖南九典制药股份有限公司董事会 湖南九典制药股份有限公司 关于实施 2024 年度权益分派期间九典转 02 暂停转股的公告 2025 年 5 月 16 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》相关规定，自2025年5月19日至2024年度权益分派股权登记日期间 九典转02暂停转股，自2024年度权益分派股权登记日后的第一个交易日起九典转 02恢复转股。在上述暂停转股期间，九典转02正常交易，敬请各位债券持有人留 意。 1、债券代码：123223 债券简称：九典转02 ...

Group 1: Sales Performance - The sales of Loxoprofen Sodium Gel Patch are normal, with rapid growth in sales volume achieved through "price for volume" strategy in the hospital market [2] - The company is increasing investment in the outpatient market, promoting rapid growth in outpatient sales revenue through "Jiuyue" brand building and channel penetration [2] Group 2: Product Development - Currently, five external preparations are on the market: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Ketorolac Gel, Lidocaine Double Cardine Cream, and Anti-inflammatory Pain Relief Patch [3] - Expected approvals for 2025 include Lidocaine Gel Patch, Indomethacin Gel Patch, Flurbiprofen Gel Patch, and Loxoprofen Sodium Patch [3] - Future approvals in 2026 are anticipated for Ketoprofen Patch, Flurbiprofen Patch, Clobetasol Soft Ointment, and Diclofenac Diethylamine Emulsion [3] Group 3: Mergers and Acquisitions Strategy - The company will consider multiple directions for mergers and acquisitions, focusing on targets that align with its development strategy, enhance the industrial chain, improve technology, and enrich the product pipeline [4] Group 4: Market Adaptation - Overseas transdermal drug products are widely used for pain relief, hormone replacement, cardiovascular, and neurological diseases, including Fentanyl Patch, Lidocaine Gel Patch, Nitroglycerin Patch, and others [5] Group 5: Production Capacity - The company currently has sufficient production capacity to meet existing demand and has reserved workshop space for future needs [6] - Short-term capacity can be increased by adding new production line equipment, while long-term plans will be developed based on operational needs [6] Group 6: Future Strategic Focus - The company aims to expand sales channels, particularly increasing penetration in the outpatient market and enhancing brand influence [7] - There will be a continued emphasis on R&D to develop new products and enrich the product line [8] - The company will optimize production processes and strengthen cost control mechanisms to ensure efficient operations and good returns for shareholders [8]

2024年度股东会的 法律意见书 二〇二五年五月 湖南省长沙市芙蓉区建湘路393号世茂环球金融中心63层 电话： 0731-8295 3778传真：0731-8295 3779 湖南启元律师事务所 法律意见书 湖南启元律师事务所 关于湖南九典制药股份有限公司 致：湖南九典制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南九典制药股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司2024年度股东会（以下简称"本 次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集人的资格、 表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《湖南九典 制药股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法律意 见书。 网站： www.qiyuan.com 湖南启元律师事务所 法律意见书 湖南启元律师事务所 关于湖南九典制药股份有限公司 2024 年度股东 ...

1、本次股东会无变更、否决议案的情形。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-036 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 2、本次股东会不涉及变更以往股东会决议的情形。 一、会议召开情况 （一）会议召开方式：本次股东会采取现场投票表决与网络投票表决相结合 的方式召开 2、网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的时间为 2025 年 5 月 15 日 9:15-15:00 期间的任意时间。 （三）现场会议召开地点：公司会议室（长沙市浏阳经济技术开发区健康大 道1号） （二）会议召开时间 （四）会议召集人：公司董事会 1、现场会议时间：2025 年 5 月 15 日 14:30 （ ...

Group 1: Company Strategy and Market Positioning - The company is focusing on three key areas for future strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes to enhance operational efficiency and shareholder value [2] - The company aims to strengthen its presence in the outpatient market while enhancing brand influence, particularly for the "JiuYue" transdermal patch brand [3] - The company plans to launch several transdermal products, including Lidocaine Gel Patch and Indomethacin Gel Patch, expected to be approved in 2025, and Ketoprofen Patch and Flurbiprofen Patch in 2026 [4] Group 2: Product Development and Competition - The company believes that the market for external anti-inflammatory drugs is currently underserved, and the two products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, will complement each other rather than compete [7] - The Loxoprofen Sodium Gel Patch has a high drug loading of 100mg per patch and is suitable for a wide range of conditions, while the Ketoprofen Gel Patch offers better drug permeability and efficacy for osteoarthritis [5] Group 3: Financial Projections and Market Risks - The company projects a revenue growth of 10-20% for the fiscal year 2025, with a similar expectation for net profit excluding non-recurring items [11][12] - The company acknowledges that its operational plans and product sales depend on various factors, including market conditions and industry policies, which introduce significant uncertainty [12] Group 4: Cost Management and Procurement Strategy - The company plans to reduce sales expenses by optimizing marketing strategies and expanding outpatient market reach [2] - The company maintains an integrated development strategy for raw materials and finished products, ensuring quality control and cost management through in-house production [10]

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-035 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的《药品补充申请批准通知书》。现将相关情况公告如下： 一、证书的主要内容 1、药品名称：右酮洛芬氨丁三醇片 2、剂型：片剂 3、规格：12.5mg（按 C16H14O3计） 4、注册分类：化学药品 5、申请内容：药品上市许可持有人变更，申请将右酮洛芬氨丁三醇片的药 品上市许可持有人由"湖南诺纳医药科技有限公司"变更为"湖南九典制药股份 有限公司"，生产场地保持不变。 湖南九典制药股份有限公司 关于公司获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 6、证书编号：2025B02007 7、上市许可持有人：湖南九典制药股份有限公司 8、生产企业：湖南九典制药股份有限公司 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品此次申请事项符合药品注册的 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-034 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 二、其他说明 公司回购股份的时间、回购股份数量、集中竞价交易的委托时间及交易价格 等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的规定。 后续公司将在回购期限内，结合市场情况适时推进股份回购工作，并根据相 关法律法规及时履行信息披露义务，敬请投资者注意投资风险。 特此公告。 湖南九典制药股份有限公司董事会 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万 ...

| 股东 名称 | 是否为控股股东 或第一大股东及 | 本次解除质押 股份数量（股） | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一致行动人 | | | | | | | | 朱志宏 | 是 | 5,200,000 | 3.14% | 1.05% | 2024/11/6 | 2025/4/30 | 国泰海通证券股 | | | | | | | | | 份有限公司 | | 朱志宏 | 是 | 1,559,000 | 0.94% | 0.31% | 2025/1/17 | 2025/4/30 | 国泰海通证券股 | | | | | | | | | 份有限公司 | | 合计 | - | 6,759,000 | 4.08% | 1.36% | - | - | - | | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-033 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股 ...